Future technologies for cell & gene therapy

Advanced therapies have been a significant disruptor in healthcare, fundamentally transforming the way diseases are treated. How are advances specific to technology continuing to drive this innovation forward? Join our panel on cutting-edge technologies, their effectiveness, and what we as a sector must still overcome to bring these treatments to the patient.

In this panel you will learn about:

• Novel gene therapy delivery systems
• Innovation in manufacturing
• Gene editing, iPSCs, and other new technologies
• Autologous vs. allogenic cell therapies
• Regulatory hurdles that these new technologies are facing

Fred Cohen

Co-founder & Chairman

Monograph Capital Partners

Deborah Phippard

CSO

Precision for Medicine

Palani Palaniappan

CTO

Pioneering Medicines at Flagship Pioneering

Dave Lennon

CEO

Satellite Bio

Robert Ang

CEO

Vor Bio

Mark McCamish

President & CEO

IconOVir Bio

Anshul Mangal

President

Precision Advance & Project Farma

moderator

Pricing & reimbursement: Unlocking the potential for ATMPs

Pressure is being applied to the ‘traditional’ healthcare reimbursement model. As novel therapies continue to propel towards commercialization, healthcare systems and manufacturers are being asked to embrace evidence-based pricing strategies to lessen the burden of upfront costs. Our panelists will discuss how stakeholders across the drug development continuum can work together to manage availability and affordability, while reducing patient-adverse outcomes for these life-saving treatments.

In this panel you will learn about:

• The current state of therapy pricing, reimbursement, and value demonstration
• Solutions for improving patient access
• How to better understand durability of effect and long-term data requests
• Shifting from rare to prevalent indications
• Understanding payer and HTA engagement in the US and EU markets

Phil Cyr

Senior Vice President

Precision Value & Health

Brett Kopelan

Executive Director

Debra of America

Janet Lambert

CEO

Alliance for Regenerative Medicine (ARM)

Michele Korfin

COO & CCO

Gamida Cell Ltd

Ross Maclean

EVP

PRECISIONheor (Precision Value & Health)

moderator

Funding CGTx: 2022 and beyond

The money dump into late-stage drug development came to a screeching halt in 2022. How do investors view the cell & gene landscape and where exactly is it headed? John Carroll and a team of experts will examine this recent downturn and find out what it’ll take to get funding back on track.

Kiran Reddy

Senior Managing Director

Blackstone

Peter Emtage

Venture Partner

Versant

Fred Cohen

Co-founder & Chairman

Monograph Capital Partners

Janis Naeve

Partner

Cota Capital

John Carroll

Editor & Founder

Endpoints News

moderator